论文部分内容阅读
目的探讨肝病患者血浆D-二聚体(D-D)和纤维蛋白原(Fib)的变化及其临床应用价值。方法对50例肝硬化患者(ChildA级12例,ChildB级20例,ChildC级18例)、20例慢性乙肝患者及30例正常对照测定其血浆D-D和Fib水平。结果肝硬化Child分级三组之间血浆D-D含量相比差异有显著性(P<0.01),而Fib含量相比差异无显著性(P>0.05)。肝硬化各组与慢性乙肝组相比,血浆D-D和Fib含量均有显著性差异(P<0.05)。肝硬化各组血浆D-D和Fib含量与正常对照组相比均有显著性差异(P<0.01)。结论血浆D-D和Fib水平与肝脏疾病的严重程度密切相关,观察血浆D-D和Fib含量的变化,有助于对肝硬化患者病情严重程度进行判断,指导临床用药治疗,对预后估计有重要参考价值。
Objective To investigate the changes of plasma D-D and fibrinogen (Fib) in patients with liver disease and its clinical value. Methods Plasma D-D and Fib levels were measured in 50 patients with cirrhosis (12 cases of ChildA, 20 cases of ChildB and 18 cases of ChildC), 20 cases of chronic hepatitis B and 30 cases of normal controls. Results There was significant difference in plasma D-D levels between the three groups (P <0.01). There was no significant difference in Fib content between the three groups (P> 0.05). Compared with chronic hepatitis B group, the levels of D-D and Fib in cirrhosis were significantly different (P <0.05). The levels of plasma D-D and Fib in cirrhosis group were significantly different from those in normal control group (P <0.01). Conclusions The levels of D-D and Fib in plasma are closely related to the severity of liver disease. Observing the changes of plasma D-D and Fib levels may help to judge the severity of liver cirrhosis patients and guide the clinical treatment. It has important reference value for prognosis estimation.